FOX NEWS: Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results


Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results



A Phase 2 trial involving an investigational monoclonal antibody drug, semorinemab, targeting the tau protein, reduced cognitive decline among adults with mild-to-moderate Alzheimer’s disease by about 44%, Swiss biotech AC Immune announced Tuesday.

via FOX NEWS https://ift.tt/3mS57V0

Subscribe for New Updates

* indicates required

Comments

Popular posts from this blog

Media call: NSF post-shutdown Q&A

Ebooks